Neon Therapeutics’ Personalized Neoantigen Vaccine NEO-PV-01 in Combination with Opdivo Shows Enhanced Progression-Free Survival Across Melanoma, NSCLC, and Bladder Cancer

July 16, 2019/BioValleyBIOON/--Neon Therapeutics is a clinical-stage immuno-TumorNeon Therapeutics, Inc. is an industry leader in the field of neoantigen-targeted therapy, dedicated to transforming cancer treatment by directing the immune system to target neoantigens. Currently, the company is leveraging its neoantigen platform to develop vaccines and T-cell therapies.

Recently, the company announced the top-line results of its ongoing multicenter Phase Ib clinical study NT-001. The study evaluated Neon Therapeutics’ personalized neoantigen vaccine candidate NEO-PV-01 in combination with Bristol-Myers Squibb’s PD-1TumorImmunotherapy Opdivo (Odivo, generic name: nivolumab) for the treatment of advanced or metastaticMelanoma, efficacy and safety in patients with smoking-related non-small cell lung cancer (NSCLC) and bladder cancer.

Data with a median follow-up of at least 12 months showed that, in all three differentTumorAmong the types, NEO-PV-01 in combination with Opdivo demonstrated prolonged and sustained improvement in progression-free survival (PFS), showing advantages compared to checkpoint inhibitor monotherapy based on historical benchmark data.

In 34 cases of metastaticMelanomaAmong the patients, with a median follow-up of 13.4 months, the median PFS was not reached; among 27 patients with metastatic NSCLC, the median PFS was 5.6 months; and among 21 patients with metastatic bladder cancer, the median PFS was 5.6 months. Top-line data from these 82 patients support the further development of NEO-PV-01, including a randomized Phase II clinical study evaluating the drug for the treatment of metastatic disease.

Neon Therapeutics’ RECON Machine Learning Platform and the Epitope Spreading Mechanism of Neoantigen Vaccines

NEO-PV-01 is an investigational personalized neoantigen vaccine from Neon Therapeutics, custom-designed and manufactured based on each patient’s unique mutational fingerprint. NEO-PV-01 incorporates Neon Therapeutics’ RECONBioinformaticsThe engine selects up to 20 neoantigen-targeting peptides, designed to elicit anti-tumor immune responses and guide T cells to target the patient.Tumorspecific neoantigens in

Currently, NEO-PV-01 is being evaluated in multiple Phase I clinical studies for the treatment of various typesTumorIn addition to NEO-PV-01, the company has two other therapies: NEO-PTC-01 and NEO-SV-01. The former is a neoantigen T-cell therapy for the treatment of solid tumors, while the latter is a neoantigen vaccine for the treatment of hormone receptor-positive (HR+) cancers.Breast Cancer(Bioon.com)

Original Source:Neon Therapeutics’ Personal Neoantigen Vaccine Study Demonstrates Prolonged Progression-Free Survival in Advanced or Metastatic Melanoma, Non-Small Cell Lung and Bladder Cancers